Infliximab and Ulcerative Colitis

Ulcerative colitis (UC) is one of the main forms of inflammatory bowel disease. The condition causes the colon and rectum to become inflamed and ulcerated.

Management of acute severe ulcerative colitis (ASUC) including

Crohn's & Colitis Foundation on X: The FDA approved Celltrion USA's ZYMFENTRA® (infliximab-dyyb), the first and only subcutaneous infliximab injection, for the treatment of moderate to severe ulcerative colitis and Crohn's disease.

Remicade (infliximab) FDA Approval History

Infliximab News, Research

JCM, Free Full-Text

Pharmaceutics, Free Full-Text

JCM, Free Full-Text

SciELO - Brazil - TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES

REMICADE® (infliximab) for Moderately to Severely Active Adult UC

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis